Revenue and Profit - The company's revenue for Q1 2024 was ¥1,237,638,493.59, a decrease of 8.72% compared to ¥1,355,800,163.83 in the same period last year[5] - Net profit attributable to shareholders was ¥177,296,535.93, down 2.74% from ¥182,299,215.54 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥101,106,457.09, representing a significant decline of 42.28% from ¥175,174,269.85 in the previous year[5] - The company’s basic earnings per share for Q1 2024 was ¥0.1266, a decrease of 2.76% from ¥0.1302 in the same period last year[5] - Net profit for Q1 2024 was CNY 54,600,065.35, down 28.0% from CNY 75,847,801.25 in the same period last year[19] - Earnings per share (EPS) for Q1 2024 was CNY 0.1266, compared to CNY 0.1302 in Q1 2023[20] Cash Flow - The net cash flow from operating activities improved to ¥112,704,408.96, a 177.31% increase from a negative cash flow of -¥145,786,103.21 in the same period last year[5] - The net cash flow from operating activities for Q1 2024 was ¥112,704,408.96, a significant improvement from a net outflow of ¥145,786,103.21 in Q1 2023[23] - Total cash inflow from investment activities reached ¥1,947,361,618.95, compared to ¥1,273,240,473.57 in the same period last year[23] - The net cash flow from investment activities was -¥1,598,240,236.20, slightly better than the -¥1,651,706,387.48 recorded in Q1 2023[23] - The total cash outflow from financing activities was ¥57,114,046.76, with a net cash flow of -¥56,814,046.76[23] - The company reported cash inflows from operating activities totaling ¥1,227,514,080.44, compared to ¥1,129,611,784.19 in Q1 2023[23] - Cash paid for purchasing goods and services was ¥639,201,866.58, a decrease from ¥767,379,134.39 in the previous year[23] Assets and Liabilities - Total assets increased by 4.04% to ¥7,745,502,353.47 from ¥7,444,681,386.84 at the end of the previous year[5] - The company's cash and cash equivalents decreased by 58.61% to ¥1,082,179,009.12, primarily due to investments in financial products[9] - Trading financial assets increased significantly from ¥764,593,455.37 to ¥2,457,779,977.84, representing a growth of about 222.5%[15] - Accounts receivable rose from ¥402,367,563.15 to ¥730,177,973.89, an increase of approximately 81.3%[15] - Inventory decreased from ¥446,579,335.09 to ¥347,493,599.47, a reduction of about 22.1%[16] - Total liabilities increased, with accounts payable rising from ¥123,500,723.65 to ¥176,348,006.67, an increase of about 42.7%[16] - The total liabilities increased to CNY 920,835,390.92 from CNY 790,180,602.21, marking a rise of 16.5%[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 102,530[12] - The largest shareholder, Renhe Group, holds 23.24% of shares, totaling 325,299,386 shares[12] - The company has a total of 15,500,000 shares held in a repurchase account, which are not included in the top ten shareholders[13] - The company reported no changes in the shareholding structure of the top ten shareholders due to margin trading activities during the reporting period[13] Research and Development - The company's research and development expenses decreased by 15.82% to ¥6,468,715.89 from ¥7,684,761.30 year-on-year[9] - Research and development expenses were CNY 6,468,715.89, down from CNY 7,684,761.30, indicating a decrease of 15.8%[19] Other Income - The company reported a 1505.70% increase in other income to ¥78,338,220.77, mainly due to higher government subsidies received compared to the previous year[9] - Other income significantly increased to CNY 78,338,220.77 from CNY 4,878,757.19, showing a substantial growth[19] Financial Reporting - The first quarter report was not audited, indicating preliminary financial results[24] - The company is set to implement new accounting standards starting in 2024, which may affect future financial reporting[24]
仁和药业(000650) - 2024 Q1 - 季度财报